Chiglitazar
Clinical data
Trade namesBilessglu
Other namesCarfloglitazar
Legal status
Legal status
  • Rx in China
Identifiers
  • (2S)-3-[4-(2-carbazol-9-ylethoxy)phenyl]-2-[2-(4-fluorobenzoyl)anilino]propanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC36H29FN2O4
Molar mass572.636 g·mol−1
3D model (JSmol)
  • C1=CC=C2C(=C1)C3=CC=CC=C3N2CCOC4=CC=C(C=C4)C[C@@H](C(=O)O)NC5=CC=CC=C5C(=O)C6=CC=C(C=C6)F
  • InChI=1S/C36H29FN2O4/c37-26-17-15-25(16-18-26)35(40)30-9-1-4-10-31(30)38-32(36(41)42)23-24-13-19-27(20-14-24)43-22-21-39-33-11-5-2-7-28(33)29-8-3-6-12-34(29)39/h1-20,32,38H,21-23H2,(H,41,42)/t32-/m0/s1
  • Key:QNLWMPLUWMWDMQ-YTTGMZPUSA-N

Chiglitazar (trade name Bilessglu) is a drug for the treatment of type 2 diabetes.[1] It is a peroxisome proliferator-activated receptor (PPAR) agonist.

In China, chiglitazar is approved for glycemic control in adult patients with type 2 diabetes when used in combination with diet and exercise.[2]

References

  1. Ji, Linong; et al. (2021). "Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)". Science Bulletin. 66 (15): 1571–1580. Bibcode:2021SciBu..66.1571J. doi:10.1016/j.scib.2021.03.019. PMID 36654286. S2CID 233650336.
  2. Deeks, Emma D. (2022). "Chiglitazar: First Approval". Drugs. 82 (1): 87–92. doi:10.1007/s40265-021-01648-1. PMID 34846697. S2CID 244716275.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.